Newsfile Corp
06 Aug 2026, 19:52 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
A class action lawsuit alleges Capricor Therapeutics failed to disclose that the FDA had not agreed to changes in the statistical analysis plan for Deramiocel before the BLA resubmission. — FDA disagreement on primary analysis plans significantly increases the risk of a Complete Response Letter (CRL) or drug rejection, which is a binary event for biotech valuations.
-0.80The lawsuit claims there is a substantial risk to the regulatory approval of Deramiocel for the treatment of Duchenne muscular dystrophy. — Directly challenges the viability of the company's core product pipeline, creating uncertainty regarding future revenue streams.
-0.70A securities class action lawsuit has been filed against Capricor Therapeutics for allegedly making materially false or misleading statements between December 17, 2025, and July 26, 2026. — Legal proceedings create financial liability and reputational damage, though often secondary to the actual regulatory risk of the drug.
-0.40Continue reading
6 related stories
Top 2 movers · tap to explore
Which stocks this story touches
The company is facing a class action lawsuit alleging misleading statements regarding clinical data and FDA approval risks for Deramiocel.
The company is mentioned in the context of a securities class action lawsuit.
The company is mentioned in the context of a securities class action investigation.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
2h ago
